The 36-month beta value for LCTX is also noteworthy at 1.34. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LCTX is 187.75M, and at present, short sellers hold a 5.64% of that float. The average trading volume of LCTX on May 07, 2024 was 942.38K shares.
LCTX) stock’s latest price update
Lineage Cell Therapeutics Inc (AMEX: LCTX) has experienced a rise in its stock price by 22.64 compared to its previous closing price of 1.06. However, the company has seen a gain of 16.07% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-07 that Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Ioana Hone – Head of IR Brian Culley – CEO Jill Howe – CFO Conference Call Participants Joe Pantginis – H.C Wainwright Jack Allen – Baird Kristen Kluska – Cantor Fitzgerald Mayank Mamtani – B. Riley Sean McCutcheon – Raymond James Michael Okunewitch – Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call.
LCTX’s Market Performance
Lineage Cell Therapeutics Inc (LCTX) has seen a 16.07% rise in stock performance for the week, with a -7.14% decline in the past month and a 25.00% surge in the past quarter. The volatility ratio for the week is 11.07%, and the volatility levels for the past 30 days are at 8.26% for LCTX.. The simple moving average for the past 20 days is 8.11% for LCTX’s stock, with a 9.09% simple moving average for the past 200 days.
Analysts’ Opinion of LCTX
Many brokerage firms have already submitted their reports for LCTX stocks, with Robert W. Baird repeating the rating for LCTX by listing it as a “Outperform.” The predicted price for LCTX in the upcoming period, according to Robert W. Baird is $5 based on the research report published on November 02, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see LCTX reach a price target of $4. The rating they have provided for LCTX stocks is “Buy” according to the report published on June 14th, 2022.
Noble Capital Markets gave a rating of “Outperform” to LCTX, setting the target price at $8 in the report published on August 19th of the previous year.
LCTX Trading at 6.33% from the 50-Day Moving Average
After a stumble in the market that brought LCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.25% of loss for the given period.
Volatility was left at 8.26%, however, over the last 30 days, the volatility rate increased by 11.07%, as shares sank -11.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.21% upper at present.
During the last 5 trading sessions, LCTX rose by +16.07%, which changed the moving average for the period of 200-days by -12.16% in comparison to the 20-day moving average, which settled at $1.1940. In addition, Lineage Cell Therapeutics Inc saw 19.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LCTX starting from BAILEY DON M, who purchase 96,155 shares at the price of $1.04 back on Feb 08 ’24. After this action, BAILEY DON M now owns 158,801 shares of Lineage Cell Therapeutics Inc, valued at $100,001 using the latest closing price.
BROADWOOD PARTNERS, L.P., the Director of Lineage Cell Therapeutics Inc, purchase 6,730,770 shares at $1.04 during a trade that took place back on Feb 06 ’24, which means that BROADWOOD PARTNERS, L.P. is holding 41,666,255 shares at $7,000,001 based on the most recent closing price.
Stock Fundamentals for LCTX
Current profitability levels for the company are sitting at:
- -2.77 for the present operating margin
- 0.91 for the gross margin
The net margin for Lineage Cell Therapeutics Inc stands at -2.41. The total capital return value is set at -0.3. Equity return is now at value -31.42, with -19.13 for asset returns.
Based on Lineage Cell Therapeutics Inc (LCTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -9.68. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 56.86.
Currently, EBITDA for the company is -24.04 million with net debt to EBITDA at 1.36. When we switch over and look at the enterprise to sales, we see a ratio of 23.81. The receivables turnover for the company is 12.01for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.14.
Conclusion
In summary, Lineage Cell Therapeutics Inc (LCTX) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
